In Brief: Guidant Ventak AV II
This article was originally published in The Gray Sheet
Executive Summary
Guidant Ventak AV II: Firm's second-generation automatic implantable cardioverter defibrillator/dual-chamber pacing system for the treatment of arrhythmias will be available in the U.S. by mid-1998, Guidant says. The firm gained FDA sign-off on a premarket approval application supplement for the 73 cc, 136-gram system in mid-December. The device incorporates the company's Endotak lead and Triad three-electrode energy defibrillation system, and offers detection and diagnostic enhancements through its Quick Start and Auto Interrogate programming features, the company says. Guidant will discontinue availability of the Ventak AV once the AV II model reaches the market...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.